JCOGの基本情報 > 研究実績 > 肺がん内科グループ

JCOGの基本情報肺がん内科グループ

更新日：2018年9月14日

  1. 論文
    1. 委員会承認の治療研究
      JCOG8502
      M Fukuoka, K Furuse, N Saijo, et al.: Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer. J Natl Cancer Inst. 83(12): 855-861, 1991.
      JCOG8803
      Y Ariyoshi, M Fukuoka, K Furuse, et al.: Concurrent Cisplatin-Etoposide Chemotherapy plus Thoracic Radiotherapy for Limited-Stage Small Cell Lung Cancer. Jpn J Clin Oncol. 24: 275-281, 1994.
      JCOG8809
      K Eguchi, H Etou, S Miyachi, et al.: A Study of Dose Escalation of Teniposide (VM-26) plus Cisplatin (CDDP) with Recombinant Human Granulocyte Colony-Stimulating Factor (rhG-CSF) in Patients with Advanced Small Cell Lung Cancer. Eur J Cancer. 30A(2): 188-194, 1994.
      JCOG8902
      K Kubota, T Tamura, M Fukuoka, et al.: Phase II study of concurrent chemotherapy and radiotherapy for unresectable stage III non-small-cell lung cancer: Long-term follow-up results. Japan Clinical Oncology Group Protocol 8902. Ann Oncol. 11: 445-450, 2000.
      JCOG9011
      H Ohmatsu, K Eguchi, T Shinkai, et al.: A Randomized Cross-Over Study of High-Dose Metoclopramide plus Dexamethasone versus Granisetron plus Dexamethasone in Patients Receiving Chemotherapy with High-dose Cisplatin. Jpn J Cancer Res. 85: 1151-1158, 1994.
      JCOG9104
      M Takada, M Fukuoka, M Kawahara, et al.: Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Results of the Japan Clinical Oncology Group Study 9104 (JCOG9104). J Clin Oncol. 20: 3054-3060, 2002.
      JCOG9106
      K Furuse, M Fukuoka, Y Nishiwaki, et al.: Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group. J Clin Oncol.16: 2126-2132, 1998.
      JCOG9110
      T Shinkai, H Arioka, H Kunikane, et al.: Phase I Clinical Trial of Irinotecan (CPT-11), 7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin, and Cisplatin in Combination with Fixed Dose of Vindesine in Advanced Non-Small Cell Lung Cancer. Cancer Res. 54: 2636-2642, 1994.
      JCOG9111
      H Asamoto, M Kawahara, F Iwami, et al.: Cisplatin plus Oral Etoposide in the Treatment of Patients with Advanced Small Cell Lung Cancer. Jpn J Clin Oncol. 28(12): 745-748, 1998.
      JCOG9202
      K Furuse, M Fukuoka, M Kawahara, et al.: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 17(9):2692-2699, 1999.
      JCOG9302
      F Oshita, K Noda, Y Nishiwaki, et al.: Phase II Study of Irinotecan and Etoposide in Patients with Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol. 15: 304-309, 1997.
      JCOG9306
      I Sekine, Y Nishiwaki, T Ogino, et al.: Phase II study of twice-daily high-dose thoracic radiotherapy alternating with cisplatin and vindesine for unresectable stage III non-small-cell lung cancer: Japan Clinical Oncology Group Study 9306. J Clin Oncol. 20: 797-803, 2002.
      JCOG9405
      A Yokoyama, Y Kurita, N Saijo, et al.: Dose-Finding Study of Irinotecan and Cisplatin plus Concurrent Radiotherapy for Unresectable stage III Non-Small-Cell Lung Cancer. Br J Cancer. 78(2): 257-262, 1998.
      JCOG9406
      M Ando, K Eguchi, T Shinkai, et al.: Phase I Study of Sequentially Administered Topoisomerase I Inhibitor (Irinotecan) and Topoisomerase II Inhibitor (Etoposide) for Metastatic Non-Small-Cell Lung Cancer. Br J Cancer. 76(11): 1494-1499, 1997.
      JCOG9408
      M Fujishiro, T Shinkai, M Fukuda, et al.: Phase I study of a weekly infusion of irinotecan hydrochloride (CPT-11) and a 14-day continuous infusion of etoposide in patients with lung cancer: JCOG trial 9408. Jpn J Clin Oncol. 30: 487-493, 2000.
      JCOG9409
      H Okamoto, K Watanabe, Y Nishiwaki, et al.: Phase II Study of Area Under the Plasma-Concentration-Versus-Time Curve-Based Carboplatin Plus Standard-Dose Intravenous Etoposide in Elderly patients with Small-Cell Lung Cancer. J Clin Oncol. 17(11): 3540-3545, 1999.
      JCOG9413
      I Sekine, Y Nishiwaki, R Kakinuma, et al.: Phase II study of high-dose dexamethasone-based association in acute and delayed high-dose cisplatin-induced emesis - JCOG study 9413. Br J Cancer. 76(1): 90-92, 1997.
      JCOG9507
      I Sekine, Y Nishiwaki, R Kakinuma, et al.: Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG9507. Br J Cancer. 88: 808-813, 2003.
      JCOG9510
      T Fujii, H Kunikane, H Okamoto, et al.: A phase II study of cisplatin and irinotecan as induction chemotherapy followed by accelerated hyperfractionated thoracic radiotherapy with daily low-dose carboplatin in unresectable stage III non-small cell lung cancer: JCOG 9510. Jpn J Clin Oncol. 39(12): 784-790, 2009.
      JCOG9511
      N Noda, Y Nishiwaki, M Kawahara, et al.: Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer. N Engl J Med. 346(2): 85-91, 2002.
      JCOG9515
      K Yoshida, T Sugiura, N Takifuji, et al.: Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer(JCOG9515). Lung Cancer. 58: 362-368, 2007.
      JCOG9601
      S Tsuchiya, Y Ohe, T Sugiura, et al.: Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601). Jpn J Clin Oncol. 31: 488-494, 2001.
      JCOG9605
      H Kunitoh, T Tamura, T Shibata, et al.: A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605). Br J Cancer. 101: 1549-1554, 2009.
      JCOG9606
      H Kunitoh, T Tamura, T Shibata, et al.: A phase II trial of dose-dense chemotherapy, followed by surgical resection and/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606). Br J Cancer. 103: 6-11, 2010.
      JCOG9608
      F Oshita, K Yamada, Y Kato, et al.: Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 52: 73-78, 2003.
      JCOG9702
      H Okamoto, K Watanabe, H Kunikane, et al.: Randomized phase III trial of carboplatin plus etoposide vs. split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG9702. Br J Cancer. 97(2): 162-169, 2007.
      JCOG9706
      K Takeda, S Negoro, M Tanaka, et al.: A phase II study of cisplatin and irinotecan as induction chemotherapy followed by concomitant thoracic radiotherapy with weekly low-dose irinotecan in unresectable, stage III, non-small cell lung cancer: JCOG 9706. Jpn J Clin Oncol. 41(1): 25-31, 2011.
      JCOG9807
      K Yamada, F Oshita, K Noda, et al.: Dose escalation study of paclitaxel in combination with fixed-dose irinotecan in patients with advanced non-small cell lung cancer (JCOG 9807). Oncology. 66: 94-100, 2004.
      JCOG9811
      H Kunitoh, T Tamura, T Shibata, et al.: A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811). Br J Cancer. 100: 464-469, 2009.
      JCOG9812
      S Atagi, M Kawahara, T Tamura, et al.: Standard Thoracic Radiotherapy With or Without Concurrent Daily Low-dose Carboplatin in Elderly Patients with Locally Advanced Non-small Cell Lung Cancer: a Phase III Trial of the Japan Clinical Oncology Group (JCOG9812). Jpn J Clin Oncol. 35(4):195-201, 2005.
      JCOG9901-DI
      N Hida, H Okamoto, Y Misumi, et al.: A phase I trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cisplatin for dry stage III non-small-cell lung cancer (JCOG9901DI). Cancer Chemother Pharmacol 69: 1625-1631, Jun 2012.
      JCOG9902-DI
      I Sekine, Y Nishiwaki, K Noda, et al.: Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI). Ann Oncol. 14: 709-714, 2003.
      JCOG9903-DI
      K Kubota, Y Nishiwaki, T Sugiura, et al.: Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903. Clin Cancer Res. 11(15): 5534-5538, 2005.
      JCOG9904-DI
      T Kurata, N Yamamoto, T Komiya, et al.: A phase I study of gemcitabine plus irinotecan for advanced NSCLC: Japan Clinical Oncology Group Trial (JCOG9904). Jpn J Clin Oncol. 40(10): 992-994, 2010.
      JCOG9910-DI
      K Naoki, H Kunikane, T Fujii, et al.: Dose-escalating and pharmacokinetic study of a weekly combination of paclitaxel and carboplatin for inoperable non-small cell lung cancer: JCOG 9910-DI. Jpn J Clin Oncol. 39(9): 569-575, 2009.
      JCOG0104
      K Takeda, S Negoro, T Tamura, et al.: Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104). Ann Oncol. 20(5): 835-841, 2009.
      JCOG0202
      K Kubota, T Hida, S Ishikura, et al: Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study. Lancet Oncol 15: 106-113, 2014.
      JCOG0207
      H Tsukada, A Yokoyama, K Goto, et al: Randomized controlled trial comparing docetaxel-cisplatin combination with weekly docetaxel alone in elderly patients with advanced non-small-cell lung cancer: Japan Clinical Oncology Group (JCOG) 0207. Jpn J Clin Oncol. 45(1):: 88-95, 2015.
      JCOG0301
      S Atagi, M Kawahara, A Yokoyama, et al.: Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol. 13: 671-678, 2012.
      JCOG0402
      S Niho, Y Ohe, S Ishikura, et al.: Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402). Ann Oncol. 23: 2253-2258, 2012.
      JCOG0509
      M Satouchi, Y Kotani, T Shibata, et al: Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509. J Clin Oncol. 32: 1262-1268, 2014.
      JCOG0605
      K Goto, Y Ohe, T Shibata, et al.: Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 17(8): 1147-1157, 2016.
      JCOG0803
      T Abe, K Takeda, Y Ohe, et al: Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: the intergroup trial JCOG0803/WJOG4307L. J Clin Oncol. 33(6):: 575-581, 2015.
      JCOG0901
      H Murakami, N Yamamoto, T Shibata, et al.: A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901). Lung Cancer 84: 67-72, 2014.
    2. グループ代表者管理の治療研究
      なし
    3. 附随研究等
      M Kawahara, M Fukuoka, N Saijo, et al.: Prognostic Factors and Prognostic Staging System for Small Cell Lung Cancer. Jpn J Clin Oncol. 27(3): 158-165, 1997.
      J Eba, H Kenmotsu, M Tsuboi, et al.: A Phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206). Jpn J Clin Oncol. 44: 379-382, 2014.
      JCOG9511
      PN Lara, T Shibata, H Fukuda, et al.: Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer1: Final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124. Cancer. 116: 5710-5715, 2010.
      JCOG9512
      N Ishizuka, Y Ohashi: The continual reassessment method and its applications: a Bayesian methodology for phase I cancer clinical trials. Stat Med. 20: 2661-2681, 2001.
      Y Ohe, T Tamura, N Saijo, et al.: Lung-term follow-up of patients with unresectable locally advanced non-small cell lung cancer treated with chemoradiotherapy: A retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG0003A). Cancer Sci. 94: 729-734, 2003
      JCOG9702
      A Rossi, H Okamoto, T Tamura, et al.: Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data. J Clin Oncol. 30: 1692-1698, 2012.
      JCOG0202
      N Sanuki-Fujimoto, S Ishikura, K Hayakawa, et al.: Radiotherapy quality assurance review in a multi-center randomized trial of limited-disease small cell lung cancer: the Japan Clinical Oncology Group (JCOG) trial 0202. Radiat Oncol. 4(1):16, 2009.
      JCOG1201
      J Eba, T Shimokawa, K Nakamura, et al: A Phase II/III study comparing carboplatin and irinotecan with carboplatin and etoposide for the treatment of elderly patients with extensive-disease small-cell lung cancer (JCOG1201). Jpn J Clin Oncol. 45(1): 115-118, 2015.
      JCOG1205/1206
      J Eba, H Kenmotsu, M Tsuboi, et al: A Phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206). Jpn J Clin Oncol. 44: 379-382, 2014.
    4. 総説・解説
      なし
  2. 主な学会発表
    1. 委員会承認の治療研究
      JCOG9104
      M Takada, M Fukuoka, K Furuse, et al.: Phase III Study of Concurrent versus Sequential Thoracic Radiotherapy in Combination with Cisplatin and Etoposide for Limited-Stage Small Cell Lung Cancer: Preliminary Results of the Japan Clinical Oncology Group. 32th Annual Meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 15: 372, May 1996.
      K Goto, Y Nishiwaki, M Takada, et al.: Final Results of a Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy (TRT) in Combination with Cisplatin (P) and Etoposide (E) for Limited-Stage Small Cell Lung Cancer (LD-SCLC): The Japan Clinical Oncology Group (JCOG) Study. 35th Annual Meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 18: 468a, May 1999.
      JCOG9106
      K Furuse, K Kubota, Y Nishiwaki, et al.: Phase III Study of Dose-Intensive Weekly Chemotherapy with Recombinant Human Granulocyte-Colony-Stimulating Factor versus Standard Chemotherapy in Extensive Stage Small Cell Lung Cancer. 32th Annual Meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 15: 375, May 1996.
      JCOG9202
      K Furuse, M Fukuoka, Y Takada, et al.: A Randomized Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination with Mitomycin, Vindesine, and Cisplatin in Unresectable Stage III Non-Small Cell Lung Cancer: Preliminary analysis. Abstract #1649: 33th Annual Meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 16: 459a, May 1997.
      JCOG9302
      K Goto, Y Nishiwaki, N Saijo, et al.: A Phase II Study of Irinotecan (CPT-11) and Etoposide (VP-16) for Metastatic Non-Small Cell Lung Cancer (NSCLC): Japan Clinical Oncology Group (JCOG) Trial. 31th Annual Meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 14: May 1995.
      JCOG9306
      I Sekine, Y Nishiwaki, R Kakinuma, et al.: Long-term results of twice-daily high-dose thoracic radiotherapy (TRT) alternating with chemotherapy (CT) of cisplatin and vindesine for unresectable stage III non-small cell lung cancer (NSCLC). JCOG study 9306. 36th Annual Meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 19: 509a, May 2000.
      JCOG9406
      M Ando, K Eguchi, T Shinkai, et al.: Phase I Study of Sequentially Administered Irinotecan and Etoposide for Metastatic Non-Small Cell Lung Cancer. 32th Annual Meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 15: 480, May 1996.
      JCOG9409
      H Okamoto, K Watanabe, K Mori, et al.: A Phase II Study of Carboplatin (CBDCA) and Etoposide (ETP) in Elderly Patients with Small Cell Lung Cancer (SCLC): Japan Clinical Oncology Group (JCOG) Study 9409. 34th Annual Meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 17: 473a, May 1998.
      JCOG9504
      H Saka, K Shimokata, S Yoshida, et al.: Irinotecan and Concurrent Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer: A Phase II Study of Japan Clinical Oncology Group (JCOG9504). 33th Annual Meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 16: 447a, May 1997.
      JCOG9507
      I Sekine, Y Nishiwaki, R Kakinuma, et al.: PhaseI/II Trial of Weekly Cisplatin (CDDP), Etoposide (ETOP) and Irinotecan (CPT) for Metastatic Lung Cancer (JCOG Study 9507). 34th Annual Meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 17: 500a, May 1998.
      I Sekine, Y Nishiwaki, R Kakinuma, et al.: Dose intensity of irinotecan (CPT) combined with weekly cisplatin (CDDP) and etoposide (ETOP) in patients (pts) with metastatic lung cancer (LC): Phase I/II study JCOG 9507. International Association for the Study of Lung Cancer 9th World Conference on Lung Cancer. Lung Cancer. 29(S1): 38, Sep 2000.
      JCOG9509
      K Kubota, R Itoh, T Kodama, et al.: Concurrent Cisplatin/Etoposide (PE) and Twice-Daily Thoracic Radiotherapy (BID TRT) followed By Weekly Dose Intensive Regimen (CODE) with Human Granulocyte-Colony Stimulating Factor (G-CSF) for Limited Stage (LS) Small Cell Lung Cancer (SCLC). 35th Annual Meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 18: 513a, May 1999.
      JCOG9510
      H Kunikane, K Watanabe, H Kunitoh, et al.: A Phase II Study of Cisplatin (CDDP) and Irinotecan (CPT-11) as Chemotherapy (CT) and Sequential Accelerated Hyperfractionated Thoracic Radiotherapy (AH-TRT) with Daily Low Dose Carboplatin (CBDCA) in Unresectable Stage-III Non-Small Cell Lung Cancer (NSCLC) (JCOG Study 9510). 35th Annual Meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 18: 513a, May 1999.
      JCOG9511
      K Noda, Y Nishiwaki, M Kawahara, et al.: Randomized Phase III Study of Irinotecan (CPT-11) and Cisplatin in Extensive-Disease Small-Cell Lung Cancer Japan Clinical Oncology Group Study (JCOG9511). 36th Annual Meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 19: 483a, May 2000.
      S Negoro, K Noda, Y Nishiwaki, et al.: A randomized phase III Study of irinotecan and cisplatin (CP) versus etoposide and cisplatin (EP) in extensive-disease small-cell lung cancer (ED-SCLC): Japan Clinical Oncology Group study (JCOG9511). International Association for the Study of Lung Cancer 9th World Conference on Lung Cancer. Lung Cancer. 29(S1): 30, Sep 2000.
      JCOG9512
      M Makino, H Tsukada, A Yokoyam, et al.: Phase I/II trial of Cisplatin (CDDP), Etoposide (ETP), and Irinotecan (CPT-11) for the treatment of advanced non-small-cell lung cancer (NSCLC). Japan Clinical Oncology Group (JCOG) study 9512. International Association for the Study of Lung Cancer 9th World Conference on Lung Cancer. Lung Cancer. 29(S1): 23, Sep 2000.
      JCOG9601
      S Tsuchiya, Y Ohe, T Sugiura, et al.: Randomized Phase I Study of Standard-Fractionated (SDF) and Accelerated-Hyperfractionated (AHF) Radiotherapy with Concurrent Cisplatin and Vindesine (PV) for Unresectable Non-Small Cell Lung Cancer (NSCLC): Japan Clinical Oncology Group (JCOG) 9601. 35th Annual Meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 18: 525a, May 1999.
      JCOG9605/9606
      K Kunitoh, T Tamura, H Fukuda, et al.: Dose intensive chemotherapy (Cx) in advanced thymoma: Initial report of Japan Clinical Oncology Group trials (JCOG9605 and 9606). 42th Annual Meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 24: 384, Jun 2006.
      JCOG9702
      H Okamoto, K Watanabe, H Kunikane, et al.: Randomized phase III trial of carboplatin (C) plus etoposide (E) vs. split doses of cisplatin (P) plus etoposide (E) in elderly or poor-risk patients with extensive disease small cell lung cancer (ED-SCLC): JCOG9702. 41st Annual Meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 23(16S): 7010, May 2005.
      A Rossi, M Di Maio, P Chiodini, et al.: COCIS individual patient data (IPD) meta-analysis: Carboplatin- or cisplatin-based chemotherapy (CT) as first-line treatment of small cell lung cancer (SCLC). 47th Annual meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 29: abstr 7022, Jun 2011.
      JCOG9706
      N Yamamoto, M Fukuoka, S Negoro, et al.: A Phase II Study of Induction Chemotherapy (IND CT) with CPT-11 and Cisplatin Followed by Thoracic Radiation (TRT) Combined with Weekly CPT-11 in Patients with Unresectable Stage III Non-Small-Cell Lung Cancer (NSCLC). 36th Annual Meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 19: 499a, May 2000.
      N Takifuji, S Negoro, M fukuoka, et al.: A Phase II Study of Induction Chemotherapy (Ind CT) with CPT-11 and cisplatin followed by thoracic radiation (TRT) combined with weekly CPT-11 in patients with unresectable stage III non-small-cell lung cancer (NSCLC): A Japan Clinical Oncology Group (JCOG) 9706 Trial. International Association for the Study of Lung Cancer 9th World Conference on Lung Cancer. Lung Cancer. 29(S1): 111, Sep 2000.
      M Kawahara, S Hosoe, M Fukuoka, et al.: A phase II study of induction chemotherapy (IND CT) with CPT-11 and cisplatin followed by thoracic radiotherapy (TRT) combined with weekly CPT-11 in patients with unresectable stage III non-small cell lung cancer (NSCLC): final results of Japan Clinical Oncology Group (JCOG) protocol 9706. 38th Annual Meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 21: 316a, May 2002.
      JCOG9811
      H Kunitoh, T Tamura, T Shibata, et al.: A randomized trial of intrapericardial (ip) bleomycin (BLM) after drainage for management of malignant pericardial effusion (MPE) in lung cancer patients (pts) : Report of a Japan Clinical Oncology Group trial (JCOG9811). 43rd Annual meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 25: 436s, Jun 2007.
      JCOG9902-DI
      I Ikuo, Y Nishiwaki, K Noda, et al.: Randmized phase II study of Cisplatin (P), Irinotecan (I), and Etoposide (E) combinations administered weekly or enery four weeks for extensive small cell lung cancer (ESCLC): JCOG9902-DI. 38th Annual Meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 21: 306a, May 2002.
      N Saijo, I Sekine, T Tamura, et al.: Randomized phase II study of cisplatin (P), Irinotecan (I), and etoposide (E), combinations administered weekly of every four weeks for extensive small cell lung cancer (ESCLC): JCOG9902-DI. International Association for the Study of Lung Cancer 10th World Conference on Lung Cancer. Lung Cancer. 41(S2): S81, Aug 2003.
      JCOG9903-DI
      K Mori, K Kubota, T Tamura, et al.: Cisplatin and etoposide plus concurrent accelerated hyperfractionated thoracic radiotherapy (TRT) followed by three cycles of irinotecan and cisplatin for the treatment of limited-stage small-cell lung cancer (SCLC); updated results: JCOG 9903-DI. 38th Annual Meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 21: 294a, May 2002.
      K Kubota, Y Nishiwaki, T Tamura, et al.: A pilot study of cisplatin and etoposide plus concurrent accelerated hyperfractionated thoracic radiotherapy (TRT) followed by three cycle of irinotecan and cisplatin for the treatment of limited-stage small-cell lung cancer (SCLC): JCOG9903-DI. International Association for the Study of Lung Cancer 10th World Conference on Lung Cancer. Lung Cancer. 41(S2): S24, Aug 2003.
      JCOG0104
      K Takeda, S Negoro, T Tamura, et al.: Docetaxel (D) versus docetaxel plus gemcitabine (DG) for second-line treatment of non-small cell lung cancer (NSCLC): Results of a JCOG randomized trial (JCOG0104). 40th Annual Meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 23: 622, Jun 2004.
      JCOG0202
      K Kubota, T Hida, S Ishikura, et al.: Randomized phase III study comparing etoposide and cisplatin (EP) with irinotecan and cisplatin (IP) following EP plus concurrent accelerated hyperfractionated thoracic radiotherapy (EP/AHTRT) for the treatment of limited-stage small-cell lung cancer (LD-SCLC): JCOG0202. 48th Annual meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 30: 7028 abstr, Jun 2012.
      JCOG0207
      H Tsukada, A Yokoyama, Y Nishiwaki, et al.: Randomized controlled trial comparing docetaxel (D)-cisplatin (P) combination with D alone in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): JCOG0207. 43rd Annual meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 25: 416s, Jun 2007.
      JCOG0301
      H Okamoto, S Atagi, M Kawahara, et al.: Updated results of a phase III trial comparing standard thoracic radiotherapy (RT) with or without concurrent daily low-dose carboplatin in elderly patients (pts) with locally advanced non-small cell lung cancer (NSCLC): JCOG0301. 48th Annual meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 30: 7017 abstr, Jun 2012.
      JCOG0402
      Y Ohe, Y Nishiwaki, A Yokoyama, et al.: Safety and efficacy trial of cisplatin (P) with vinorelbine (V) followed by gefitinib (G) and concurrent thoracic radiotherapy (TRT) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC): Japan Clinical Oncology Group (JCOG) 0402. 46th Annual meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 28: 15s, Jun 2010.
      JCOG0509
      Y Kotani, M Satouchi, M Ando, et al.: A phase III study comparing amrubicin and cisplatin (AP) with irinotecan and cisplatin (IP) for the treatment of extended-stage small cell lung cancer (ED-SCLC): JCOG0509. Proc Am Soc Clin Oncol. 30: 7003 abstr, 2012.
      JCOG0803
      T Abe, A Yokoyama, K Takeda, et al.: Randomized phase III trial comparing weekly docetaxel (D)-cisplatin (P) combination with triweekly D alone in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): An intergroup trial of JCOG0803/WJOG4307L. 47th Annual meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 29: abstr 7509, Jun 2011.
      JCOG0605
      K Goto, Y Ohe, T, Seto, et al.: A randomized phase III study of cisplatin (CDDP), etoposide (ETOP) and irinotecan versus topotecan as second-line chemotherapy in patients with sensitive relapsed small-cell lung cancer (SCLC): Japan Clinical Oncology Group study JCOG0605. 50th Annual meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 32: Jun 2014.
      JCOG0901
      H Daga, H Murakami, N Yamamoto, et al: Phase II study of amrubicin in patients with refractory or resistant relapsed small cell lung cancer: Japan Clinical Oncology Group study (JCOG0901). Ann Oncol. 23: 492-498, 2012.
    2. グループ代表者管理の治療研究
      なし
    3. 附随研究等
      P Lara, M Redman, H Lenz, et al.: Cisplatin (Cis)/etoposide (VP16) compared to cis/irinotecan (CPT11) in extensive-stage small cell lung cancer (E-SCLC): Pharmacogenomic (PG) and comparative toxicity analysis of JCOG9511 and SWOG0124. 43rd Annual meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 15: 390s, Jun 2007.
      P Lara, K Chansky, T Shibata, et al.: Cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer (E-SCLC): Final "common arm": Comparative outcomes analysis of JCOG 9511 and SWOG 0124. 45th Annual meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 27(15s): 8027, Jun 2009.
      H Katayama, K Takeda, H Fukuda, et al.: An integrated analysis of comprehensive geriatric assessment (CGA) in elderly patients with non-small cell lung cancer (NSCLC) (JCOG1115-A). 48th Annual meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 30: abstr 6112, Jun 2012.
      S Atagi, J Mizusawa, S Ishikura, et al.: Randomized trial of thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer (NSCLC): Long-term follow-up of Japan Clinical Oncology Group (JCOG) Study JCOG0301. 53rd Annual meeting of the American Society of Clinical Oncology. Proc Am Soc Clin Oncol. 35: Abstr 8532, Jun 2017.
    4. 総説・解説
      JCOG9008、JCOG9009、JCOG9509、JCOG9704、JCOG9909-DI
      堀之内 秀仁、 大江 裕一郎：JCOG肺がん内科グループ. 腫瘍内科. 21（5）：599-609, 2018.
トップへ戻る